BIOGEN INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 171.4 BRL | -2.16% |
|
-.--% | -16.49% |
| 05-03 | HSBC Adjusts Price Target on Biogen to $342 From $339, Maintains Buy Rating | MT |
| 04-30 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
| Sales 2024 * | 9.52B 48.21B 758B | Sales 2025 * | 9.55B 48.34B 760B | Capitalization | 31.67B 160B 2,520B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.9B 9.6B 151B | Net income 2025 * | 2.21B 11.19B 176B | EV / Sales 2024 * | 3.64 x |
| Net Debt 2024 * | 3.01B 15.26B 240B | Net Debt 2025 * | 536M 2.71B 42.64B | EV / Sales 2025 * | 3.37 x |
| P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
14.5
x | Employees | 7,570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biogen Inc.
More recommendations
More press releases
More news
| 1 day | -2.16% | ||
| 1 month | -2.16% | ||
| 3 months | -15.42% | ||
| 6 months | -13.89% | ||
| Current year | -16.49% |
1 month
171.36
171.36
Current year
171.36207.90
1 year
171.36251.82
3 years
157.76355.98
5 years
143.40360.00
10 years
126.01360.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 13/11/22 | |
| Director of Finance/CFO | 60 | 14/08/20 | |
Nicole Murphy
COO | Chief Operating Officer | - | 31/12/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 31/12/09 |
William Hawkins
BRD | Director/Board Member | 70 | 18/06/19 |
Caroline Dorsa
CHM | Chairman | 64 | 02/01/10 |
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
217.5
USD
Average target price
285.9
USD
Spread / Average Target
+31.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.89% | 88.14B | |
| +1.45% | 40.51B | |
| +51.20% | 24.62B | |
| -14.60% | 15.65B | |
| -13.92% | 12.07B | |
| -7.87% | 11.97B | |
| -39.40% | 11.61B | |
| +5.62% | 8.81B | |
| -5.26% | 8.5B |
- Stock Market
- Equities
- BIIB Stock
- BIIB34 Stock
